Skip to main content
رجوع
CRMD logo

CorMedix Inc.

جودة البيانات: 100%
CRMD
NASDAQ Healthcare Biotechnology
KWD 6.61
▲ KWD 0.15 (2.32%)
القيمة السوقية: 522.52M
نطاق اليوم
KWD 6.52 KWD 6.71
نطاق 52 أسبوعًا
KWD 5.60 KWD 17.43
حجم التداول
883,286
متوسط 50 يوم / 200 يوم
KWD 7.16 / KWD 10.71
الإغلاق السابق
KWD 6.46

Quick Summary

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (627 نظير)

المقياس السهم وسيط القطاع
P/E 3.2 0.3
P/B 1.3 3.0
ROE % 66.6 3.7
Net Margin % 52.3 3.8
Rev Growth 5Y % 535.7 10.0
D/E 0.4 0.2

السعر المستهدف للمحللين

Hold
KWD 13.75 +108.0%
Low: KWD 13.00 High: KWD 16.00
مكرر الربحية المستقبلي
7.73
ربحية السهم المستقبلية
KWD 0.83
نمو ربحية السهم (تقدير)
+0.0%
الإيرادات المقدّرة
306.52M

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2030 KWD 1.98
KWD 1.87 – KWD 2.10
 555.23M 1
FY2029 KWD 1.34
KWD 1.27 – KWD 1.42
 423.59M 1
FY2028 KWD 0.91
KWD 0.38 – KWD 1.49
 348.14M 5

Dividend History

Yield

0.00%

Payout Ratio

0.00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

النقاط الرئيسية

Revenue grew 535.65% annually over 5 years — strong growth
ROE of 66.56% indicates high profitability
Net margin of 52.31% shows strong profitability
Debt/Equity of 0.37 — conservative balance sheet
Generating 172.79M in free cash flow
P/E of 3.20 — trading at a low valuation

النمو

Revenue Growth (5Y)
535.65%
Revenue (1Y)617.03%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
66.56%
ROIC20.32%
Net Margin52.31%
Op. Margin48.17%

الأمان

Debt / Equity
0.37
Current Ratio2.01
Interest Coverage53.97

التقييم

P/E Ratio
3.20
Forward P/E7.73
P/B Ratio1.29
EV/EBITDA3.50
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 617.03% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 535.65% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 311.71M Net Income (TTM) 163.06M
ROE 66.56% ROA 19.74%
Gross Margin 88.46% Operating Margin 48.17%
Net Margin 52.31% Free Cash Flow (TTM) 172.79M
ROIC 20.32% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.37 Current Ratio 2.01
Interest Coverage 53.97
Dividends
Dividend Yield 0.00% Payout Ratio 0.00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio 3.20 Forward P/E 7.73
P/B Ratio 1.29 P/S Ratio 1.68
PEG Ratio -0.01 Forward PEG N/A
EV/EBITDA 3.50 Fwd EV/EBITDA N/A
Forward P/S 1.70 Fwd Earnings Yield 12.94%
FCF Yield 33.07%
Market Cap 522.52M Enterprise Value 525.61M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 311.71M 43.47M 0.0 65,408.0 190,936.0
Net Income 163.06M -17.93M -46.34M -29.70M -28.21M
EPS (Diluted) 2.04 -0.30 -0.91 -0.74 -0.75
Gross Profit 275.75M 40.28M -205,562.0 61,674.0 41,998.0
Operating Income 150.14M -22.36M -48.96M -30.62M -29.44M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 826.14M 118.85M 82.06M 62.04M 68.95M
Total Liabilities 420.84M 34.19M 11.92M 6.98M 6.15M
Shareholders' Equity 405.31M 84.66M 70.14M 55.06M 62.80M
Total Debt 148.91M 517,013.0 667,632.0 802,433.0 923,801.0
Cash & Equivalents 145.83M 40.65M 43.64M 43.37M 53.32M
Current Assets 350.47M 114.58M 79.45M 59.55M 66.47M
Current Liabilities 174.27M 33.84M 11.40M 6.31M 5.35M

درجات الاستراتيجيات

This stock passed the criteria for 4 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#288 of 1052
56
Custom Capital Light Compounder
#4 of 218
83
Custom Contrarian Investing (David Dreman)
#34 of 670
76
Value Value Investing (Warren Buffett)
#24 of 203
55

النشاط الأخير

دخل Cash Flow Compounder
Mar 24, 2026
دخل Capital Light Compounder
Mar 24, 2026
دخل Contrarian Investing (David Dreman)
Mar 24, 2026
دخل Value Investing (Warren Buffett)
Mar 24, 2026